Access to anticancer and orphan medicines through compassionate use programs and named patient basis in seven European countries
We recommend minimizing disparities between CUPs and NPBs across Europe to ensure equitable access for patients with high unmet medical needs. Reducing these differences is essential to protect patients from feeling compelled to travel abroad or bear the financial burden of obtaining medicines that are not authorized in their home country.
Authors
- Hendrika C. Post
- Nahum Rosenberg (ORCID: https://orcid.org/0000-0001-8786-1361)
- Carla E. M. Hollak (ORCID: https://orcid.org/0000-0003-0464-1078)
- Hanneke W.M. van Laarhoven (ORCID: https://orcid.org/0000-0003-1274-5643)
- Anna M.G. Pasmooij (ORCID: https://orcid.org/0000-0003-0641-3829)
- Tim Schutte (ORCID: https://orcid.org/0000-0002-4096-0917)
- Imke H. Bartelink (ORCID: https://orcid.org/0000-0001-9602-3407)
- Samuel Jacob De Visser
Institutions
- Dutch Cancer Society (NL)
- Pharmo Institute (NL)
- Medicines Evaluation Board (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105855
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00